The overarching goal of this project is to determine whether severity of baseline sleep disruption impacts treatment retention and treatment phase progression; sleep normalizes over a 6 month treatment period; and whether sleep normalization reduces mood and cognitive dysfunction in a population of patients who are being treated with buprenorphine as part of medication assisted treatment for opioid use disorder.